Tag: in-vivo
-
In-vivo gene editing, Part 2 — delivery is the rate-limiting step, and why that confines the field to the liver
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. Delivery-performance figures (editing efficiency, knockdown) are largely company, conference or preclinical (NHP/mouse) data and are attributed as such in the text; safety events are attributed to regulatory/source documents and unresolved…
-
The in-vivo gene-editing landscape — one-shot, lifelong lipid lowering has arrived at the headline, but delivery, safety and irreversibility are the real bottlenecks
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and editing-efficiency figures are attributed to the sponsoring trial or company; many are company press releases or conference presentations rather than peer-reviewed data (noted inline). Safety events are…
Uthando Nethemba 